contact us jpkrencn

お知らせ

企業動向

あなたはここにいる:ホーム > お知らせ > 企業動向 > Convalife and Medici...

Convalife and Medicilon announced a strategic pact to jointly conduct preclinical research

著者:medicilon   アップロード:2020-06-29  閲読回数:

Chuansha, Shanghai, June 29, 2020. -- Convalife and Medicilon signed a strategic pact, initiating a long-term cooperation between the two companies.

Convalife and Medicilon announced a strategic pact to jointly conduct preclinical research

Based on previous cooperation and the mutual trust, Medicilon and Convalife achieved consensus on the partnership that Medicilon will assist Convalife in new drug development utilizing its integrated pharmaceutical R&D service platform. According to the pact, Convalife will deeply cooperate with Medicilon on multiple projects of their "First-in-Class" or "Best-in-Class" new drug R&D. The cooperation is anticipated to accelerate the process of new drug development and IND filing, to offer better solutions for unsatisfied clinical requirements worldwide.

上の:Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug

下に:Medicilon assisted Guangshengtang in consistency evaluation of the generic drug Lamivudine Tablets